Kornimate/medical-research-clean huggingface dataset:
an observational study of gp verbal reminders upon cervical screening

Conditions: HPV-Related Cervical Carcinoma; Physician-Patient Relations

Summary: cervical cancer screening is offered to all women in the united kingdom (uk) between the ages of 24.5 and 64 years of age. the majority of screening is performed in primary care and the rate remains stubbornly below 80%, despite an automated national invitation system. this study is designed to assess the effectiveness of a physician invitation during a telephone or face-to-face primary care appointment upon non responders of automated invitations, to increase the uptake of cervical screening.

it is estimated that between 800 and 2,000 deaths a year are now prevented due to the effectiveness of the uk's national cervical screening programme and mortality rates have dropped by over 75% since the 1970s. these statistics corroborate the importance of the screening programme in reducing mortality from cervical cancer. cervical screening rates in the uk remains stubbornly below 80% and interventions are needed to attract the 20% who are missing out on screening. this prospective observational study is designed to measure the impact of a physician intervention in a usual healthcare environment, amongst a heterogeneous patient population to yield replicable real-world results. the intervention arm will receive a physician intervention to inform them of their overdue screening status, remind them of the importance of cervical screening and guide them to book a screening appointment. the screening rate in the intervention arm will be compared to a control made up of patients seen by other clinicians and receiving unstructured reminders. the results will assist physicians in deciding whether a structured intervention is anymore effective than the unstructured advice currently given at improving screening rates in the non responder population.

Eligibility criteria:
inclusion criteria: * registered patient with a cervix * non responder to cervical screening invitation exclusion criteria: * incorrectly reminded i. coding errors ii. human error * temporary patients i. did not remain registered for minimum of 6 months following intervention * screening refusal * inappropriate to include i. terminal illness ii. prolonged hospitalisation iii. death due to non-cervical cancer attributable cause

Keywords: cervical screening primary health care physician intervention
study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy

Conditions: Prostate Cancer; Prostatectomy

Summary: the purpose of this study is to look at blood and tissue samples for changes following the use of sunitinib malate. additionally, we would like to find out if the drug, sunitinib malate, is safe and works in men with prostate cancer. sunitinib malate , also known as sutent, is approved by the u.s. food and drug administration (fda), for treatment of tumors of intestines and kidney but it is being tested in research studies for use in men with prostate cancer.

eligible patients will be treated with 50 mg once daily for four weeks followed by one to two weeks off treatment prior to undergoing radical prostatectomy. patients with palpable disease (ct2-3) and patients with 3 or more positive prostatic biopsies from one lobe may undergo an additional study of ifp monitoring before treatment and during week 4 of study treatment. safety and tolerability of sunitinib malate therapy at this dose and schedule in this patient population will be assessed. extensive correlative science evaluations, including assessment of physiologic, cellular, molecular and genetic changes during treatment with sunitinib malate, will be performed

Eligibility criteria:
inclusion criteria: * histologic evidence of adenocarcinoma of the prostate deemed candidates for curative rrp * intermediate or high risk, clinically localized disease * adequate organ function * patients must be surgically sterile or must agree to use effective contraception during the period of therapy * select imaging to rule out metastasis will be done as clinically indicated * signed and date informed consent document exclusion criteria: * prior treatment for prostate cancer * major surgery or radiation therapy within 4 weeks of starting the study treatment * nci ctcae grade 3 hemorrhage within 4 weeks of starting therapy * history of or known metastatic prostate cancer * any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. * ongoing cardiac dysrhythmias of nci ctcae grade 2 or greater * qtc interval \> 500 msec on baseline ekg * hypertension that cannot be controlled by medications (\>150/100 mm hg despite optimal medical therapy). * pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication * known active infection * concurrent treatment on another clinical trial. supportive care trials or non-treatment trials, e.g. qol, are allowed. * other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
safety study in patients with multiple sclerosis treated fingolimod or other approved disease-modifying therapies

Conditions: Multiple Sclerosis

Summary: the purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of ms, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.


Eligibility criteria:
inclusion criteria: * patients that as part of their routine clinical care and according to the locally approved label, are either; * starting fingolimod at time of study entry. * starting another approved dmt or started within maximum 6 months prior to study entry. * patients, or a able legal representative of the patient, who are willing to provide written informed consent. fingolimod patients will constitute the fingolimod cohort while patients with the other dmt will constitute the parallel cohort exclusion criteria: * patients previously or currently treated with a cytotoxic agent (e.g. mitoxantrone, cladribine, alemtuzumab) or natalizumab * patients participating simultaneously in another study with inclusion/exclusion criteria more restrictive than the label or an interventional study unless this is a study on fingolimod lasting 1 month maximum other protocol-defined inclusion/exclusion criteria may apply

Keywords: multiple sclerosis fingolimod observational study
testing a reduced conditioning regimen fb2a2 preceded by a fractionated radio-immunotherapy (rit) with 90y-epratuzumab before allogeneic stem cell transplantation for patients with lymphocyte b cd22 positive acute lymphoblastic leukemia

Conditions: Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia

Summary: determination of the maximum tolerated dose (mtd) of fractionated rit with epratuzumab radiolabeled with yttrium-90 (90y-epratuzumab) preceding a reduced conditioning regimen fb2a2 before allogeneic stem cell transplantation.

* physical examination (screening and follow-up) * complete blood counts (screening and follow-up) * dosage of flt3-ligand in plasma (screening and follow-up) * blood ionogramme, creatinine hepatic work-up (screening and follow-up) * left ventricular ejection fraction at pre-implant assessment * immunization test (screening and follow-up) * bone marrow aspiration or/and blood cd 22 immunophenotype for minimal residual disease evaluation (screening and follow-up) * all exams which were initially abnormal and which are necessary for response evaluation and all exams which are needed in case of relapse suspicion. * pharmacokinetic of 90y-hll2

Eligibility criteria:
inclusion criteria: * age ≥ 18 * acute lymphoblastic leukemia (all) cd22 + b-type in rc1 with high risk * b-cell acute lymphoblastic leukemia (all) cd22+ beyond rc1. * expression of cd22 ≥ 30% in tumor population evaluated by flow cytometry or immunohistochemistry at diagnosis stage or relapse stage. * hla-identical donor intra family or not, without major hla mismatch (9 / 10th accepted) without contra-indication for stem cell mobilization * ecog (eastern cooperative oncology group) ≤ 2 * having or not received previously epratuzumab * eligible for an allograft with reduced conditioning regimen * with a signed informed consent * patient in age of children bearing with adequate contraception * patient affiliated to or beneficiary of the national health service exclusion criteria: * t-cell all * known hypersensibility to 90y-dota-hll2 * immunization against hll2 for patients having already received one or several injections of this antibody * patient eligible for myeloablative conditioning regimen * other prior malignancies must have had at least a 2-year disease-free interval with the exception of successfully treated carcinoma skin cancer or carcinoma in situ of the cervix. * patient with progressive psychiatric condition. * hiv positive, hepatitis b-antigen positive, or hepatitis c positive patients who need a treatment * pregnant or breast-feeding women * women with childbearing potential without effective contraception * serious concomitant and uncontrolled infection * usual contraindications in the allogeneic transplant: * adult patient protected by the french law

Keywords: cd22 positive- lymphoblastic leukemia-rit-yttrium
perioperative chemoradiotherapy for potentially resectable gastric cancer

Conditions: Stomach Neoplasms

Summary: rationale: adjuvant chemoradiation considered as standard of care after curative surgery for adenocarcinoma of stomach and gastroesophageal cancer. preoperative chemotherapy in the in locally advanced gastric cancer results in significant tumoral downstaging with improved rate of curative resections. purpose: to evaluate feasibility and safety of combination of preoperative chemotherapy and postoperative chemoradiation for locally advanced adenocarcinoma of stomach and gastroesophageal cancer


Eligibility criteria:
inclusion criteria: 1. histologically confirmed primary adenocarcinoma, poorly differentiated carcinoma, or carcinoma not otherwise specified, of stomach or gastro-esophageal junction. 2. t2-4 n0-3 m0. t1 tumors are eligible if t1n1-3 3. disease must be clinically limited to the stomach or gej. 4. pre-treatment port-a-cath insertion obligatory 5. no prior chemotherapy. 6. no prior radiotherapy. 7. patients must be surgical candidates as determined by the treating surgeon. 8. adequate organ function defined as: 9. patients must have an ecog performance status \< 1. 10. patients must be able to sign the informed consent document. exclusion criteria: 1. tis (in-situ carcinoma) and tumors determined to be tin0 following endoscopy, endoscopic ultrasound and ct scanning. 2. patients with primary carcinomas of the esophagus. 3. prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the past 5 years, or prior esophageal or gastric surgery. 4. patients with evidence of metastatic disease are not eligible. 5. new york heart association class iii or iv heart disease. 6. severe co-morbid conditions or nonmalignant illness whose control may be jeopardized by complications of the study treatment. 7. pregnant or lactating women or men unable or unwilling to practice contraception are excluded. 8. any history of prior malignancy (other than non-melanoma skin cancer, in-situ cervical cancer, or superficial transitional cell bladder cancer). 9. clinically significant hearing loss. 10. patients with a history of seizure disorder who are receiving phenytoin, phenobarbital, or other antiepileptic medication. 11. patients who cannot fully comprehend the therapeutic implications of the protocol or comply with its requirements. 12. patients with any medical or psychiatric condition or disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study

Keywords: neoadjuvant chemotherapy adjuvant chemoradiotherapy adenocarcinoma of stomach and gastroesophageal junction
intraoperative icg fluorescence imaging for peritoneal carcinomatosis detection

Conditions: Peritoneal Carcinomatosis; Gastric Cancer

Summary: background. peritoneal carcinomatosis is a frequent and deadly localization of gastric cancer. available imaging techniques have a low accuracy in detecting small peritoneal nodules, and direct laparoscopic visualization may fail too. a more accurate staging technique would be advantageous for individualization of therapeutic path. indocyanine green (icg) fluorescence imaging has been reported as a tool for visualizing small peritoneal seedings due to the "enhanced permeability and retention" (epr) effect of cancer nodules. aim. to explore the feasibility and effectiveness of fluorescence-enhanced peritoneal carcinomatosis detection in patients with gastric cancer undergoing staging laparoscopy. methods. this prospective, multicentric, single arm study will include patients with gastric cancer, without a radiological suspicion of peritoneal carcinomatosis, undergoing staging laparoscopy. an intravenous injection of icg is given at different dosage and at different timepoints before the intervention. during the staging laparoscopy, the abdominal cavity exploration is performed using standard white-light, and subsequently using fluorescence imaging. suspicious nodules are harvested, until a maximum of 5 per patient, and sent for definitive histological examination. peritoneal washing is also harvested for cytologic assessment in all cases. the eventual benefit of fluorescence imaging in terms of additional peritoneal lesions that were not detected during standard white-light imaging is evaluated. discussion. this study will establish if fluorescence imaging increases sensitivity and/or specificity of staging laparoscopy in detecting peritoneal carcinomatosis from gastric cancer. improved accuracy may translate in better care path selection.


Eligibility criteria:
inclusion criteria: 1. age of ≥18years 2. ability to provide written informed consent 3. histologically confirmed gastric adenocarcinoma or oesophago-gastric junction adenocarcinoma siewert 2 and 3 4. ct\>1 5. cm0 (clinical staging: no metastases) 6. staging laparoscopy is indicated by the internal work-up protocol 7. staging laparoscopy is in accordance with nccn (national comprehensive cancer network) guidelines exclusion criteria: 1. pregnancy 2. iodine allergy/sensibility 3. clinical p1 (defined as high probability of peritoneal carcinomatosis at imaging) 4. investigator judgement that the patient should not participate for any reason
the efficacy and safety of entecavir treatment of patients with acute on chronic hepatitis b liver failure

Conditions: Liver Failure

Summary: to evaluate therapeutic efficacy and predicting factors of entecavir for treating patients with acute on chronic hepatitis b liver failure (achblf). a total of 108 patients with achblf were allocated into either a treatment group (etv group, n=53) or a control group (n=55). the hbv dna level, liver function and survival condition of the patients were observed for 48 weeks after enrollment. the factors possibly related to entecavir treatment efficacy were also identified.


Eligibility criteria:
inclusion criteria: * achblf was diagnosed according to the criteria from the apasl in march 200815 and the program of prevention and cure for viral hepatitis and liver disease amended by the national symposium on viral hepatitis and liver disease in september 2000. * age \>18 years * hbv dna \> 3log10 copy/ml exclusion criteria: * pregnant or lactating women. * diagnosed or suspected as hepatic carcinoma patients. * cases with any serious disease besides chb, including heart disease, immunologic disease, malignant tumor, etc. * patients hypersensitive to nucleoside or nucleoside (acid) analogues or with a history nucleoside antiviral drug treatment. * a history of drug abuse or alcohol abuse. * hepatic encephalopathy degree iv patients who were unable to take orally administered drugs. * a history of using immunomodulator including steroids * conclusive evidence of other co infection s: anti-hav-igm positive, anti-hcv positive, anti-hev positive, anti-hiv positive, autoimmunity liver diseases, wilson disease, etc.

Keywords: hepatitis b acute on chronic liver failure (achblf) entecavir treatment predicting
body movement imitation and perspective perception among psychiatric patients

Conditions: Schizophrenia; Depression

Summary: the ability to understand the other's perspective and respond accordingly is the most important normal process of daily social life and is probably one of the foundations of human existence. this capability is reflected, inter alia, as an imitation - an important and effective form of learning which is very developed in humans. when we are required to imitate a particular movement, speed of response depends on the perspective of the movement. imitative response is implemented faster when the movement is observed from first-person perspective, than if the motion is presented from the perspective of a third party. while healthy individuals don't find it difficult to imitate, or to understand the other's emotion expression, there are psychiatric populations (such as autism and schizophrenia) who find it difficult to demonstrate these capabilities (park, matthews et al. 2008). beyond these capabilities impairment, schizophrenic patients have difficulty distinguishing between their arm movements and those of a foreign hand and find it difficult to leave the boundaries of egocentric interpretation of reality and adopt the other's point of view. these behavioral disorders arise from defects in the network of mirror neurons (buccino and amore 2008; langdon, coltheart et al. 2010). therefore, the investigator expect that schizophrenic patients will not see a preference for movements that will be displayed in first-person perspective from the same movements that will be displayed from the perspective of a third party. consequently, the investigator speculate that these subjects will not exhibit differences at imitating the response of which will be presented from different perspectives (jackson, meltzoff et (al. 2006.


Eligibility criteria:
inclusion criteria: 1. men and women aged 20-65. 2. subjects who met the criteria for diagnosis of major dsm-iv for schizophrenia or unipolar depression. 3. subjects with normal or corrected vision. 4. subjects who sign informed consent for their participation in the experiment exclusion criteria: 1. patients with acute disorder, or an unstable patient. especially neurological disorders or head injuries. 2. drug abuse in the past year. 3. lack of jurisdiction, such as people with mental retardation or dementia. 4. assessed with high suicide risk. 5. patients which are compulsory hospitalized. 6. pregnant women
intermittent fasting versus diet to stop hypertension on metabolic risk profile in nonalcoholic fatty liver patients

Conditions: Fasting, Intermittent; Diet; Hypertension; Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease

Summary: this study was conducted to compare between the effect of intermittent fasting and diatery approach to stop hypertension on metabolic risk profile in nonalcoholic fatty liver patients.

non-alcoholic fatty liver is a liver disease linked to obesity, insulin resistance, type 2 diabetes, hypertension, hyperlipidemia, and metabolic syndrome. the subtype, non-alcoholic steatohepatitis, can lead to liver fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. the prevalence of non-alcoholic fatty liver disease is increasing at the same rate as obesity, with the global prevalence estimated at 25%. by 2020, the burden of non-alcoholic fatty liver is expected to exceed that of communicable disease in most regions.

Eligibility criteria:
inclusion criteria: * non-alcoholic fatty liver patients diagnosed by radiological ultrasound * bmi \>30 * all patients are sedentary lifestyle with little or no exercise. * high lipid profile (total cholesterol \> 200, ldl \> 130, tags \> 150) patients by laboratory investigation. * high fasting insulin level \> 20mlu/ml \& high fasting glucose level \>100, hba1c \> 5.7 \& high homa- ir \> 2.5 patients by laboratory investigation. * high inflammatory markers (il6) patients. * age ranged from 30 to 40 years old. exclusion criteria: * alcoholic fatty liver patients. * cirrhosis patients. * diabetes patients. * cognitive impaired patients. * history of epilepsy patients. * cardiac pacemaker patients. * anemic patients * pregnancy
multimodal neuroimaging of stress and reward cues to assess alcoholism risk and relapse

Conditions: Alcohol Dependence

Summary: extending previous findings, and applying a novel multi-method translational approach, this project hypothesizes that there are alcohol-related neuroendocrine and neural changes observable in acute and protracted abstinence, and which can accurately classify future relapse and treatment outcome in separate alcohol dependent (ad) patient samples, thereby validating them as biomarkers of relapse, with potential clinical utility as prognostic markers in identifying and treating those most susceptible to relapse.


Eligibility criteria:
inclusion criteria: * male and females, aged 18-60 years; * good health as verified by screening examination; * able to read english and complete study evaluations; * able to provide informed written and verbal consent; * ad sample must meet dsm-5 criteria for aud as assessed using scid-i and have positive alcohol urine toxicology screens on admission to study; while hc group must never have met criteria for aud, with non-binging and nonhazardous alcohol intake levels( men: below15 drinks/week; women: less than 8 drinks/week); and with negative alcohol urine toxicology screens; page exclusion criteria: * meet current criteria for dependence on another psychoactive substance, excluding nicotine; (ii) current use of opiates or past history of opiate abuse/dependence; * regular use of anticonvulsants, sedatives/hypnotics, prescription analgesics, other antihypertensives, anti-arrhythmics, antiretroviral medications, ssri's naltrexone, antabuse; * psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania); * significant underlying medical conditions such as a history of seizure disorder, cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude subjects from fully cooperating or be of potential harm during the course of the study; * any psychotic disorder or current axis i psychiatric symptoms (excluding anxiety disorders) requiring specific attention, including need for psychiatric medications; * hypotensive individuals with sitting blood pressure below 90/50 mmhg; * women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by pregnancy tests during initial medical evaluation, and assessed every two weeks during the course of the study); and * those with metal in their body excluded from mri due to safety.